JP2016535009A5 - - Google Patents

Download PDF

Info

Publication number
JP2016535009A5
JP2016535009A5 JP2016524060A JP2016524060A JP2016535009A5 JP 2016535009 A5 JP2016535009 A5 JP 2016535009A5 JP 2016524060 A JP2016524060 A JP 2016524060A JP 2016524060 A JP2016524060 A JP 2016524060A JP 2016535009 A5 JP2016535009 A5 JP 2016535009A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
exosome
cells
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016524060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535009A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/061245 external-priority patent/WO2015058148A1/en
Publication of JP2016535009A publication Critical patent/JP2016535009A/ja
Publication of JP2016535009A5 publication Critical patent/JP2016535009A5/ja
Pending legal-status Critical Current

Links

JP2016524060A 2013-10-17 2014-10-17 抗体依存性エキソソーム治療の方法 Pending JP2016535009A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361892352P 2013-10-17 2013-10-17
US61/892,352 2013-10-17
US201462038734P 2014-08-18 2014-08-18
US62/038,734 2014-08-18
PCT/US2014/061245 WO2015058148A1 (en) 2013-10-17 2014-10-17 Antibody dependent exosome therapy

Publications (2)

Publication Number Publication Date
JP2016535009A JP2016535009A (ja) 2016-11-10
JP2016535009A5 true JP2016535009A5 (enExample) 2017-11-09

Family

ID=52828772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524060A Pending JP2016535009A (ja) 2013-10-17 2014-10-17 抗体依存性エキソソーム治療の方法

Country Status (4)

Country Link
US (1) US20160243192A1 (enExample)
EP (1) EP3057662A4 (enExample)
JP (1) JP2016535009A (enExample)
WO (1) WO2015058148A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011097480A1 (en) 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
WO2013070324A1 (en) 2011-11-07 2013-05-16 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for diagnosis and treatment of disease
US20170035700A1 (en) 2014-04-11 2017-02-09 University Of Louisville Research Foundation, Inc. Coated edible plant-derived microvesicle compositions and methods for using the same
AU2016288643A1 (en) * 2015-07-02 2018-02-22 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for delivery of miRNA and methods for treatment of cancer
JP7075594B2 (ja) 2015-11-18 2022-05-26 ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド 神経細胞の細胞外小胞
WO2017087685A1 (en) 2015-11-20 2017-05-26 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
CA3058782A1 (en) 2017-04-03 2018-10-11 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
US10815520B2 (en) 2017-04-07 2020-10-27 University Of Louisville Research Foundation, Inc. Nanovesicles, methods, and systems for diagnosis and prognosis of cancer
EP3438250B1 (en) * 2017-07-31 2022-12-07 Rheinische Friedrich-Wilhelms-Universität Bonn Cell derived extracellular vesicles for the treatment of diseases
WO2019104242A1 (en) 2017-11-22 2019-05-31 University Of Louisville Research Foundation, Inc. Edible plant-derived nanoparticles for regulation of gut microbiota
CN107998149B (zh) * 2017-12-11 2020-05-19 浙江大学 NK细胞外泌体及相关miRNA在抗菌和抗肿瘤中的应用
US11512315B2 (en) * 2018-02-12 2022-11-29 Codiak Biosciences, Inc. Methods and compositions for macrophage polarization
IL266153A (en) * 2019-04-18 2019-07-31 Aharon Anat Extracellular vesicles derived from t cells containing a chimeric antigen receptor
EP3965829A4 (en) 2019-05-06 2023-05-24 Malcolm, Thomas ADAPTED HYPOIMMUNE NANOVESICULAR DELIVERY SYSTEM FOR CANCER TUMORS
WO2020247675A1 (en) * 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
US12097222B2 (en) 2019-06-06 2024-09-24 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
US11607428B2 (en) 2019-06-06 2023-03-21 Spiritus Therapeutics, Inc. Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases
US20210130782A1 (en) * 2019-10-28 2021-05-06 Augusta University Research Institute, Inc. Engineered Exosomes to Detect and Deplete Pro-Tumorigenic Macrophages
KR20230004424A (ko) * 2019-11-04 2023-01-06 아루나 바이오, 인크. 세포외 소포체 및 항체 전달을 위한 그의 용도
CN111450249A (zh) * 2020-03-09 2020-07-28 杨静悦 miRNA-320a的表达促进物在制备抑制肿瘤细胞药物中的应用
JP2023536665A (ja) * 2020-08-05 2023-08-28 オハイオ・ステイト・イノベーション・ファウンデーション アダプターポリペプチドおよびその使用方法
WO2022149779A1 (ko) * 2021-01-11 2022-07-14 주식회사 엑소코바이오 과발현된 Fc 수용체 또는 이의 일부를 포함하는 엑소좀 및 이의 제조방법
WO2022158836A1 (ko) * 2021-01-21 2022-07-28 주식회사 엑소코바이오 목적 단백질 또는 펩타이드가 융합가능한 Fc 수용체 또는 이의 일부를 포함하는 재조합 엑소좀 및 이의 용도
WO2023081109A1 (en) * 2021-11-05 2023-05-11 Malcolm Thomas Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
CN115887491A (zh) * 2022-11-10 2023-04-04 中国药科大学 一种具有骨髓靶向功能的工程化双特异性外泌体/囊泡制剂及其制备方法和应用
US20240318185A1 (en) * 2023-03-20 2024-09-26 MAM Holdings of West Florida, L.L.C. Mesenchymal stem cell-derived microribonucleic acid-mediated treatments for the prevention and targeted treatment of cancer and other disorders
US20250170174A1 (en) * 2023-11-29 2025-05-29 Mor Research Applications Ltd. Methods of treating leukemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160142A0 (en) * 2001-08-17 2004-06-20 Anosys Inc Methods and compounds for the targeting of protein to exosomes
JP2006517970A (ja) * 2003-02-14 2006-08-03 ユニバーシティ オブ サザン カリフォルニア 癌免疫療法のための組成物及び方法
IL161899A0 (en) * 2004-05-10 2005-11-20 Hoffman Arnold Kit for treatment of cancer
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
WO2011097480A1 (en) * 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease

Similar Documents

Publication Publication Date Title
JP2016535009A5 (enExample)
Li et al. Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer
Yin et al. Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy
Vanmeerbeek et al. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Braunstein et al. Targeting toll-like receptors for cancer therapy
AU2018352221B2 (en) Peptides and nanoparticles for intracellular delivery of mRNA
CN108392633B (zh) Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用
JP2019504105A5 (enExample)
JP2019506862A5 (enExample)
JP2017518302A5 (enExample)
US20210046156A1 (en) Altering inflammatory states of immune cells in vivo by modulating cellular activation states
KR20150080592A (ko) Tec 패밀리 키나제 억제제 애쥬번트 요법
Ranji et al. Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance
RU2017126610A (ru) Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47
US12516318B2 (en) Targeting glioblastoma stem cells through the TLX-TET3 axis
Carew et al. Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas
JP2017514800A5 (enExample)
Wang et al. Current development of glioblastoma therapeutic agents
JP2019531293A5 (enExample)
Baykara Current therapies and latest developments in cancer treatment
JP2018516936A5 (enExample)
Yu et al. Recombinant cell-permeable HOXA9 protein inhibits NSCLC cell migration and invasion
Lahooti et al. MiRNAs as anti-angiogenic adjuvant therapy in cancer: synopsis and potential
JP2016526021A5 (enExample)
WO2010099139A3 (en) Combination of an either an anti-igf-ir- antibody or an igf binding protein and a small molecule igf-ir kinease inhibitor